Dave Risinger

can you please comment on 29 activation of amylin one relative to calcitonin. And also, if you could discuss its half-life

Could you please provide some more details on that, the opportunity to improve upon the profile of J&J's bravado

could you please discuss the outlook for accelerating growth as Humira's absolute dollar declines diminish in coming years

could you please discuss your vision for leveraging your global aesthetics commercial footprint to sell obesity drugs in the future

the industry is facing three major US Government risks, actions that are harming biopharma innovation, including actions significant FDA disruption

could you please frame your long-term commercial vision for this candidate, including what some may underappreciate about how broadly it could potentially be adopted

Could you please discuss your agenda for M&A, including the potential to leverage your franchise strength in related product categories

Could you provide some quantification on the uptake of Repatha by cash-pay patients and, I do not know if it is meaningful enough yet

I was just hoping that you could maybe just call out the top two or three pipeline cards that are turning over that could be most impactful for Amgen

can you please discuss how you see the potential for IV biosimilars to compete with hyaluronidase subcutaneous versions which are set to experience significant uptake ahead of the opportunity to la...

could you just talk us through when you're expecting generic entry in major markets ex U.S

could you just talk about the hypotension risk and how you would contextualize that for us

could you please discuss milvexian's profile, including its potency relative to asundexian

are IRA prices for the first 10 price-controlled drugs in 2026, including Eliquis currently being renegotiated

help us better understand what you think investors underappreciate about milvexian's likelihood of success

the more disappointing results in the risperidone subgroup and whether the company believes that risperidone DDIs with Cobenfi may have the efficacy

Could you comment on how Bristol leadership team and board are engaging differently today with Washington to defend the industry

can you comment on growth prospects for YERVOY going forward as well

the worse that the LOEs perform in '25, the better the setup for the trajectory of growth for the company in '26

Could you talk about your vision for its role in IBD treatment paradigms and the readouts that we should be focused on

how you plan to position it relative to TREMFYA given the similar indications

I was hoping that you could just frame your vision for employer coverage in the United States

I'm hoping that you can comment, Dave, on discussions with the Trump administration on tariffs outside of the 232 investigation

I wanted to just pivot to the long-acting relaxin candidate VOLENRELAXIN. And so the company had advanced it into a CKD trial in the fourth quarter

I was just hoping you could clarify the comment earlier. I think there was a comment about additional PBM coverage coming in March

if you could just please provide an update on your restructuring of corporate strategy and business development operations at the company?

Could you comment on your expectations for SV and Mevro pivotal readouts this year?

could you talk a little bit more about MET233I, which I believe is now numbered 3945. Specifically, the bias of amylin relative to calcitonin

Could you just comment on the legal process ahead? I know that Pfizer is arguing that Novo's acquisition of Metsera would be anticompetitive

has Pfizer been helping the administration understand the very strong support that the Chinese government provides to local biotech companies

could you just help us understand his ability as HHS Secretary to remove U.S. vaccine liability protections

highlight the pipeline candidates in late-stage development that we'll have cards turning over in the near term

could you talk a little bit more about the souped-up version of DUPIXENT that's in development

The industry is facing three major U.S. government risks, specifically actions that are harming biopharma innovation

discuss the need to combine myostatin with an Activin blocker to treat obesity and optimize body composition

does GERNAVICS need to achieve more employer opt-ins and more Tier 2 formulary positions

could you please provide a little bit more color on your expectations for the profile of this candidate

I was wondering if you could comment on the number of commercial lives with unrestricted access

How is Vertex engaging with Washington leadership to educate elected leadership about the importance of both proven medical science and biotechnology innovation

regarding the PBM with 22 million lives, are those within the 94 million figure or on top? And are they unrestricted or restricted lives

what are the company's plans to take action to prevent other countries from doing the same as that single country

do you expect to be able to pay the rebates that are necessary to get broad unfettered access to suzetrigine